These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18288932)

  • 1. Differentiating the dementias. Revisiting synucleinopathies and tauopathies.
    Hickey C; Chisholm T; Passmore MJ; O'Brien JD; Johnston J
    Curr Alzheimer Res; 2008 Feb; 5(1):52-60. PubMed ID: 18288932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates.
    Hou CE; Carlin D; Miller BL
    Can J Psychiatry; 2004 Mar; 49(3):164-71. PubMed ID: 15101498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.
    Josephs KA; Petersen RC; Knopman DS; Boeve BF; Whitwell JL; Duffy JR; Parisi JE; Dickson DW
    Neurology; 2006 Jan; 66(1):41-8. PubMed ID: 16401843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interface between tauopathies and synucleinopathies: a tale of two proteins.
    Galpern WR; Lang AE
    Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
    Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
    Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.
    Vacchi E; Lazzarini E; Pinton S; Chiaro G; Disanto G; Marchi F; Robert T; Staedler C; Galati S; Gobbi C; Barile L; Kaelin-Lang A; Melli G
    Brain; 2022 Aug; 145(8):2755-2768. PubMed ID: 35485527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases.
    Cummings J
    Am J Geriatr Psychiatry; 2021 Apr; 29(4):375-383. PubMed ID: 32819825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
    Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
    Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ; Hausser-Hauw C; Duyckaerts C
    Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies.
    Ferrer I; Hernández I; Boada M; Llorente A; Rey MJ; Cardozo A; Ezquerra M; Puig B
    Acta Neuropathol; 2003 Nov; 106(5):419-35. PubMed ID: 12955398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia in idiopathic Parkinson's syndrome.
    Fuchs GA; Gemende I; Herting B; Lemke MR; Oehlwein C; Reichmann H; Rieke J; Emmans D; Volkmann J
    J Neurol; 2004 Sep; 251 Suppl 6():VI/28-32. PubMed ID: 15675722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
    Zouambia M; Fischer DF; Hobo B; De Vos RA; Hol EM; Varndell IM; Sheppard PW; Van Leeuwen FW
    Proteomics; 2008 Mar; 8(6):1221-36. PubMed ID: 18283660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson-related dementias.
    Boeve BF
    Neurol Clin; 2007 Aug; 25(3):761-81, vii. PubMed ID: 17659189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.
    Aarsland D; Litvan I; Salmon D; Galasko D; Wentzel-Larsen T; Larsen JP
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1215-20. PubMed ID: 12933921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
    Chalmers KA; Love S
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential diagnosis of Alzheimer's disease.
    Geldmacher DS; Whitehouse PJ
    Neurology; 1997 May; 48(5 Suppl 6):S2-9. PubMed ID: 9153154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual pathology of corticobasal degeneration and Parkinson's disease in a patient with clinical features of progressive supranuclear palsy.
    Mooney T; Tampiyappa A; Robertson T; Grimley R; Burke C; Ng K; Patrikios P
    Neurol India; 2011; 59(6):887-90. PubMed ID: 22234205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathies: one disease or many?
    Bouchard M; Suchowersky O
    Can J Neurol Sci; 2011 Jul; 38(4):547-56. PubMed ID: 21672694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.